00000000

2 PROVIDER INFORMATION Practice Name

1 PATIENT INFORMATION

PLEASE ATTACH: COPY OF INSURANCE CARD (FRONT/BACK) AND DEMOGRAPHIC SHEET Missing Information May Delay Turn-Around-Time and Reporting of Results.

Collection Date:

Clinical Laboratory Improvement Amendments

GIREQUISITION 3216 South Alston Avenue, Durham, North Carolina 27713 Phone: 919-341-1256 • Fax: 919-341-1256 CLIA # 34D2131299 • CAP# 8190193 Laboratory Director: Dr. Manoj Tyagi, PhD. NRCC - CC, FAACC/FACB

Eacility name (if applicable)		Attach Facesheet of patient info	Address		
Facility name (if applicable)		Attach Facesneet of patient info	City	State	Zip
Patient Name (Last)	(First)	(Middle)	-		2ιμ
Date of Birth	Race	Ethnicity	Phone Zip	Fax	
Social Security Number		Gender	Physician Name		NPI #
· · · · · · · · · · · · · · · · · · ·			Are you a mobile provider 🗌 YES 🗌 NO) If yes, fill out sectio	n #1 in its entirety.
Address			Does patient live in 🗌 Residential Home		
City	State Zip	Phone	4 BILLING INFORMATION	_	_
		ark all mandatory billing sections	Please bill my credit card: AMEX	MasterCard 🗌 Visa	Discover
s this patient a SKILLED (Me		, ,	Name as it appears on card:		
Primary Insurance	Policy #	Group#	Account #:		
Person Insured	Self/Spouse	DOB of Insured	Expiration Date: CVC:	<u></u>	
			Amount:		Date:
Secondary Insurance	Policy #	Group#	I have been notified of the test cost and underst	tand that my credit car	d will be charged the full amou
Person Insured	Self/Spouse	DOB of Insured	I have been notified of the test cost and understand that my credit card will be charged the full amoun for the testing. Patient Signature Section, please add "Patient signature is required for patients with		
Prior Authorization #			TRICARE insurance. Patient/Guardian Signature:		
TEST SELECTION CHECK APPLICABLE BOXES ALLERGIES:		· · · · · · · · · · · · · · · · · · ·	Type / Location:		
ALLERGIES:			Renal FXN: 🗆 N	NML 🗆 ABNL Hepa	atic FXN: 🗌 NML 🗌 ABNL
Blastocystis/Blastocystis hominis Campylobacter jejuni Campylobacter upsaliensis Campylobacter coli Chlamydia trachomatis Clostridium difficile Clostridium perfringens (CPE, alpha) Clostridioides difficile Toxin A/B Cryptosporidium spp. Cyclospora cayetanensis		 Salmonella enterica Shigella spp. Staphylococcal enterotoxins A, B Staphylococcus aureus Vibrio cholerae Vibrio parahaemolyticus Vibrio vulnificus Yersinia enterocolitica Adenovirus (Intestinal) Astrovirus 	Aminoglycoside Resistance AmpC beta lactamase ACT/MIR, FOX, ACC Group Class A beta lactamase CTX-M1 (15), M2 (2), M9 (Class A beta lactamase SHV, KPC Groups Class B metallo beta lactamase IMP, NDM, VIM G Class D oxacillinase OXA-48, -51 Extended Spectrum Betalactamases Resistance Fluroquinolone Resistance Genes qnrA1, qnrA2, Macrolide Lincosamide Streptogramin Resistan Methicillin Resistance Gene mecA Tetracycline Resistance Genes tetB, tetM Trimethoprim/Sulfamethoxazole Resistance dfr Vancomycin Resistance Genes VanA, VanB	(9), M8/25 Groups 9 Gene TEM G236S 9 qnrB(qnrS) ce ermB, ermC, ermA	driven interpretati of your patient's specific infection a anibiotic resistanc markers for effecti antibiotic recom- mendations consis tent with Antibioti Stewarship.
 Dientamoeba fragilis E. coli 0157 		 Enterovirus (pan) A,B,C,D68 Norovirus GI/GII 	MEDICAL NECESSITY MUST BE COMPLETED ICDs Listed for Convenience Only - Please document applicable ICD-10 Codes.		ICD 10 Codes
 Entamoeba histolytica Enteroaggregative E. coli (Enteroaggregative E. coli (Rotavirus A Rotavirus C	□ K10.9 Unspecified abdominal pain □ R10.817 Generalized abdominal tenderness		
Enteroaggregative E. coli (E. Coli (E. Coli)			K29.70 Gastritis, Unspec. w/o Bleeding		
Enteropathogenic E. coli (EPEC)			K29.9 Gastroduodenitis, Unspecified	nspecified 🗌 R10.84 Abdominal Pain, Generalized	
Enterotoxigenic E. coli (ETEC)			K30 Functional Dyspepsia	R11.10 Vomiting,	
Giardia lamblia			K51.90 Unspecified Ulcerative Colitis		n vomiting, unspecified
 Giardia intestinalis Hypervirulent C. difficile O2 	7 (CD hyper)		K51.90 Noninfective gastroenteritis and colitis, unspecified	R18.0 Malignant ascites	
Shigella/Enteroinvasive E. c			K52.89 Other specified noninfective gastroenteritis	R18.8 Other ascites R18.00 later ab derviced and achie availing unserviced	
Shiga toxin producing E. coli (STEC)		and colitis K57.30 Diverticulosis of Colon (w/o mention of	R19.00 Intra-abdominal and pelvic swelling, unspecified		
Verotoxin positive E. coli		hemorrhage)	R19.05 Periumbilic swelling, mass or lump R19.06 Enigastric swelling, mass or lump		
Helicobacter pylori Regionance chiralleider		□ K58.9 Irritable Bowel Syndrome	R19.06 Epigastric swelling, mass or lump R19.07 Constrained intra abdominal and polyic swelling		
 Plesiomonas shigelloides Pseudomonas aeruginosa 		K59.1 Functional diarrhea	 R19.07 Generalized intra-abdominal and pelvic swelling R19.09 Other intra-abdominal and pelvic swelling 		
			K85.9 Acute Pancreatitis		· •
			K92.1 Blood in Stool	 R19.30 Abdominal rigidity, unspecified R19.4 Change in bowel habit 	
Patient Consent I am voluntarily seeking laboratory service and hereby consent to provide a sample as requested. I			R10.0 Acute abdomen R10.815 Pariumbilis abdominal tanderness	R19.5 Other fecal abnormalities	
			R10.815 Periumbilic abdominal tenderness	R19.5 Other fecal abnormalities R19.7 Diarrhea	
have the right to refuse testing, be revoked by me at any time wi laboratory my right to insurance any insurance policy, self-insure further authorize payment of be	but I understand this ith written notificatio e benefits that may b ed health plan, Medic enefits directly to the sponsibility concerni	may impact my treatment. This agreement can on and is valid until revoked. I hereby assign to the e payable to me for services provided arising from are or Medicaid in my name or on my behalf. I laboratory. I understand acceptance of insurance ng payment for laboratory services and that I am	R10.816 Epigastric abdominal tenderness Medical Provider Consent This test is medically necessary for the risk assess pairment, symptom, syndrome or disorder. The re and treatment decisions. By my signature below, health care provider. I have explained the purpos nity to ask questions and/or seek further counsel.	sment, diagnosis or det esults will determine m I indicate that I am the se of the test. The patier	y patient's medical manageme referring physician or authori. nt has been given the opportu-

Patient Signature:

Date:

Medical Provider Signature:

Date:

v121221

